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In 2008, we saw the withdrawal of aprotinin from the US markets after preliminary results from a large, randomized
clinical trial in Canada. This drug, a potent antifibrinolytic, was used primarily in complex and/or redo cardiac surgery
as an adjunct to decrease postoperative bleeding and complications. The Canadian study raised questions previously
brought up in similar studies—does aprotinin increase the risk of mortality and renal failure after cardiac surgery?
Recently, a re-review of the Canadian data noted flaws in the study, as well as in the interpretation of the results.
The present review revisits the aprotinin controversy. (J Thorac Cardiovasc Surg 2012;144:998-1002)InMay of 2008, the results of the Blood Conservation Using
Antifibrinolytics in a Randomized Trial (BART) were pub-
lished,1 although the results and corresponding data had
been a matter of speculation for months before publica-
tion.2-4 BART was a multicenter, blinded, randomized
trial of 2331 high-risk cardiac surgery patients comparing
aprotinin (Trasylol; Bayer Pharmaceuticals Corp, West
Haven, Conn) with 2 lysine analogs, tranexamic acid
(Cyklokapron; Pfizer Inc, New York, NY) and epsilon-
aminocaproic acid (Amicar; Xanodyne Pharmaceuticals,
Inc, Newport, Ky). The studywas prompted in part by a con-
tinuing controversy of the risk/benefit profile of aprotinin,
with this concern increasing during the study by observa-
tional studies questioning the safety of aprotinin.5-7 This
controversy seemed to have no end, and despite literally
thousands of publications, no clear answer could be
found, in part, perhaps, because of the statistical
machinations performed to try and match 2 or more
groups of patients (and treatments) to test a hypothesis.8
Even the well-thought out, well-planned BARTwas not im-
mune from questions regarding the study design and analy-
sis.9 Subsequently, enrollment into the aprotinin treatment
arm of the BARTwas halted because of concerns presented
to the drug safety monitoring board that there was an appar-
ent increase in mortality associated with the drug.
Even while the BART was progressing, other centers
were reporting their own results comparing aprotinin with
the other 2 antifibrinolytic agents. Pagano and colleagues10
retrospectively compared 3481 patients who had undergone
cardiac procedures using aprotinin with 4355 patients who
had not received the drug. They found no increase in either
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undergoing primary coronary artery bypass grafting, the in-
dication for which the drug was approved. A similar finding
was seen for patients undergoing off-pump coronary artery
bypass grafting.11 Furnary and colleagues12 retrospectively
analyzed prospectively collected data from more than
15,000 patients from 12 centers contributing to the Merged
Cardiac Registry. They found that when the use of trans-
fused packed red blood cells was accounted for in their
risk model, the risk of renal failure in the face of transfusion
was significant (P<.0001; odds ratio [OR], 1.23/transfused
packed red blood cells) and that the addition of the transfu-
sion variable to the risk model attenuated the ‘‘.purported
independent [e]ffect of aprotinin (P ¼ .231) on ARF [acute
renal failure].’’12 They concluded that aprotinin use did not
independently increase the risk of renal failure in cardiac
surgery patients.12 In contrast, Schloss and colleagues13 re-
ported that although aprotinin’s negative effect was inde-
pendent of baseline renal function, a negative effect on
mortality was still present.
Before the publication of the BART results and based on
preliminary data, Health Canada requested Bayer, Inc. to
suspend marketing of the drug in Canada. Health Canada
was followed shortly thereafter by the European Medicines
Agency, which cited the BART in determining that the ben-
efits of the drug no longer outweighed the risks. Subse-
quently, worldwide marketing of aprotinin was frozen by
Bayer. In Canada, a limited access program was put into
place to make aprotinin available to physicians on a case-
by-case basis in situations in which the benefits outweighed
the risks, especially because no other equivalent product
was authorized in Canada. In the United States, the drug
was voluntarily removed from clinical access in 2008, al-
though technically it remained approved by the Food and
Drug Administration (FDA) and, as was the case in Canada,
was theoretically available on a compassionate use basis.
The withdrawal of this drug from the routine armamentar-
ium of cardiac surgeons and anesthesiologists was met
with mixed reactions. Those who had considered this to
be a dangerous drug had some level of vindication by the re-
sults of BART, but others who believed the drug played
a significant role in reducing blood loss were left searching
for alternatives. The alternatives were obvious—switch toery c November 2012
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BART ¼ Blood Conservation Using
Antifibrinolytics in a Randomized
Trial
FDA ¼ Food and Drug Administration
OR ¼ odds ratio
TXA ¼ tranexamic acid(or continue using) Amicar (Xanodyne Pharmaceuticals,
Inc) or tranexamic acid (TXA), or use nothing at all.
As surgeons began switching, reports started to trickle in
relating to the benefit (or risk) of these alternatives. Martin
and colleagues14 found, in neonatal cardiac surgery, that the
conversion from aprotinin to Amicar led to a significant in-
crease in postoperative blood loss, although no differences
were seen in the transfusion requirements or major clinical
outcomes. The use of TXA also came under scrutiny, with
its relationship to seizures, including in patients undergoing
hypothermic arrest.15-18 A meta-analysis by Ngaage and
Bland19 suggested that ‘‘Given the potential for increase
[d] neurological complications, the current trend towards
indiscriminate use of tranexamic acid for all cardiac pa-
tients needs to be re-evaluated.’’ Likewise, the purported
downside of using aprotinin did not disappear with the
loss of this drug. One strong advocate for the withdrawal
of the drug stated on the 60 Minutes news show that by
his calculations, 1000 lives were lost per month because
of this drug; however, after the drug was pulled from the
market, there did not appear to be an improvement in the
Society of Thoracic Surgeons mortality data. One thousand
US cardiac deaths each month would be difficult to hide.
What was seen by some was an increase in blood use with-
out an effect on renal failure or early mortality,20,21 as well
as an increase in off-label use of recombinant factor VIIa.22
No evidence was seen of an improvement in mortality by
the lack of the use of aprotinin.
There remained patient populations outside of BART for
whom aprotinin was thought by some to have a beneficial
effect. Pasquali and colleagues23 compared aprotinin with
Amicar, TXA, and no antifibrinolytic agent in 22,258 pedi-
atric cardiac surgery patients and found that compared with
no drug, aprotinin was associated with a significant reduc-
tion in combined hospital mortality/bleeding requiring sur-
gical intervention (OR, 0.81), with this finding more
pronounced in the redo sternotomy subgroup (OR, 0.57).
A comparative analysis with the antifibrinolytic agents
showed efficacy similar to that of Amicar and improved out-
comes compared with TXA,23 a finding the investigators
also reported in a larger study.24 Similar findings were re-
ported by Wilder and colleagues25 in their study of 423 ne-
onates, despite the patients in the aprotinin group having
a greater baseline creatinine. The conflicting resultsThe Journal of Thoracic and Cacontinued with a smaller retrospective study showing a det-
rimental effect on renal function (compared with Amicar) in
children but an increase in platelet and fresh-frozen plasma
usage with nonaprotinin treatment.26 Manrique and col-
leagues27 proposed that when the preoperative risk factors
were taken into account, there did not appear to be an in-
creased risk of renal failure in the pediatric cardiac surgery
population. Another study showed no difference in out-
comes between aprotinin and TXA in the pediatric popula-
tion.28 Other beneficial effects of aprotinin were noted in
patients undergoing the Fontan procedure, specifically an
anti-inflammatory, protective role,29 a finding suggested
to result from attenuation of tumor necrosis factor-a,
interleukin-10, matrix metalloproteinase-8, and matrix
metalloproteinase-9 in aprotinin patients compared with
TXA patients.30
For high-risk patients, Karkouti and colleagues31 retro-
spectively evaluated 15,365 cardiac patients, 1017 of
whom received aprotinin, and created a matched-pair co-
hort of 1544 for propensity scoring. Aprotinin was associ-
ated with increased acute renal dysfunction; however,
when patient risk status was included, aprotinin signifi-
cantly lowered mortality (OR, 0.6) and massive blood loss
(OR, 0.7) and had a nonsignificant effect on renal injury
(OR, 1.1, 95% confidence interval, 0.7-1.7).31
After the BART, similar studies continued to suggest an
effect on long-termmortality associated with aprotinin. Sta-
mou and colleagues32 used propensity matching to compare
aprotinin with Amicar. They found that although aprotinin
did decrease the rate of blood product usage and re-
exploration, an increase occurred in in-hospital cardiac ar-
rest and late mortality.32 Another propensity-matched study
did not show a benefit in terms of blood product usage
(compared with TXA) or short-term mortality but found
an increase in the risk of postoperative dialysis.33 Addition-
ally, previous meta-analyses were revisited because of the
BART outcomes. An earlier Cochrane analysis in 2007
had demonstrated the positive aspects of antifibrinolytic
therapy, including a reduction in blood loss and the need
for transfusion. The benefit of aprotinin compared with
TXA appeared to be increased for high-risk patients.34 Af-
ter the BART, there appeared to be a significant risk of death
(relative risk, 1.39) with most of the data contributing to the
added risk coming from the BART.35 Before the Cochrane
revision, Rosen36 criticized the 2007 analysis because of
the inclusion of small studies in the meta-analysis, espe-
cially if the specified outcome was not a part of the original
study design. A similar update on a previously published
blood conservation guideline by the Society of Thoracic
Surgeons and Society of Cardiovascular Anesthesiologists
also required revision to reflect the findings of BART.37,38
In a survey of cardiac surgeons in Great Britain, 33% of
those responding believed that the withdrawal of aprotinin
had hurt their patients; most respondents did not perceiverdiovascular Surgery c Volume 144, Number 5 999
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that the withdrawal of the drug had made their patients
better.39 In a large series from China comparing 1700
patients before the cessation and 2200 patients after the
cessation of aprotinin availability, the use of blood products
increased significantly.40 For patients undergoing coronary
artery bypass grafting, the same group showed no effect of
aprotinin on mortality (P ¼ .45), long-term mortality
(P ¼ .21), or major adverse cardiac/cerebrovascular events
(P ¼ .82).41 Interestingly, the increased use of blood prod-
ucts itself was associated with a greater incidence of renal
dysfunction, not less, such as would have been predicted
by those believing that aprotinin was a major contributor
to postoperative renal failure. The increased use of blood
products after aprotinin withdrawal also correlated with
the increased duration of mechanical ventilation and an
overall decrease in arteriolar/alveolar oxygenation.40 This
follows what has been published relating the risks of blood
transfusion and transfusion-related acute lung injury.
Single-center experiences from Emory University, the
University of Chicago, and Wake Forest University have
all noted an increase in blood usage after the cessation of
aprotinin.42-44 Clearly, no drug is without risks, and we,
as a profession, must be very careful how we review and
interpret the published data, science, and evolving
technologies. As noted by Sundt,4 the repercussions of
BART went beyond the withdrawal of a single drug; this
event served as a notice as to how we, as surgeons, worked
with industry, as well as the often preconceived notions
(both pro and con) that influence how we practice our trade.
Recently, an extensive review of the BART data by
Health Canada determined that the withdrawal had been
premature. This analysis (available from: http://www.hc-
sc.gc.ca/dhp-mps/medeff/eacvhp-ccvrps/eap-gce_trasylol/
final_rep-rap-eng.php) found disagreement with the pub-
lished conclusions (and global reaction) of the BART
data. First, an extensive review of multiple clinical trials
and postmarket studies supported the benefits of aprotinin
when used appropriately and ‘‘on-label’’ (ie, for routine cor-
onary artery bypass grafting). Few clinical trials for higher
risk patients were available, although epidemiologic studies
demonstrated that this was the population that the drug was
being primarily used for, including in the BART. Second,
the reviewers noted that compared with the 2 other antifibri-
nolytics in the BART, aprotinin unexplainably prolonged
the partial thromboplastin time. This resulted in lower doses
of heparin in the aprotinin arm of the study. The impact of
this lower dose on the outcomes is not immediately known
but it might mirror the initial concerns with aprotinin mon-
itoring during cardiopulmonary bypass using the activated
clotting time versus the ecarin clotting time. Third, Health
Canada concluded that the study had not been designed to
reliably determine the risk of death relative to the 2 other
drugs in the study and that the increase in deaths in the1000 The Journal of Thoracic and Cardiovascular Suraprotinin arm could have been due to chance. From these
conclusions, Health Canada determined that the risk profile
of aprotinin remained favorable when used appropriately.
Furthermore, they approved lifting the previous withdrawal
notification, with the caveat that additional package
warnings regarding renal risks, abnormal activated partial
thromboplastin time measurements, the risk of underanti-
coagulation with heparin, and the risk of death when used
outside of approved indications be added.
Since Health Canada’s action, on February 12, 2012, the
European Medicines Agency recommended lifting the ban
on aprotinin.45 The findings of the European Medicines
Agency mirrored those of Health Canada, finding fault
with the heparin dosing disparities, inappropriate monitor-
ing of anticoagulation, and exclusion of selective patient
data from the initial analysis. Whether the drug is ever mar-
keted again in the United States might reflect more the tort
environment than the desire of surgeons to revisit this drug.
After 6 or more years of controversy, a number of reports
supporting renal dysfunction/failure, and larger ones dem-
onstrating no such effect, we have been left with an uncon-
trolled human experiment brought on by the withdrawal of
a drug from the market. It appears that such human experi-
mentation has not proved that lives are saved by not having
the drug. Rather it seems that blood usage has increased,
and perhaps some harm has been done. We need to learn
a number of collective lessons from this series of events.
Returning to the observation of Sundts4—can we envi-
sion other parts of our practice in which we are creating
new aprotinin controversies for the future? Every time we
use recombinant factor VIIa (NovoSeven, Novo Nordisk
Inc., Princeton, NJ), dowe consider what the FDA approved
the drug for? Every timewe stent an aortic dissection, dowe
stop and think about what the devices are approved for?
Probably not, because in our own mental map, we know
that when someone is bleeding to death, using factor VIIa
might be all that is left to try. The newest available proteins
for thrombosis treatment include fibrinogen concentrates
and prothrombin concentrates. The use of these agents to
stop bleeding will certainly create a hypercoagulable state
in some patients. Is it the medication’s ‘‘fault’’—or a lack
of understanding by physicians of the dynamic process, as
well as an inability to highly individualize therapy? When
the motor vehicle accident patient presents to the emer-
gency room with bleeding transaction, thoracic endovascu-
lar stent grafting can usually be done safely and expediently,
especially when the open expertise might not be available.46
Thus, the dilemma for our profession—how do we, or can
we, expand the indications for current technology and ther-
apeutics without losing sight of the continuing need for rig-
orous, evidence-based practice? Clearly, industry will not
support randomized trials for every indication we, as surgi-
cal teams, believe are reasonable. These companies are
driven by business opportunity costs. To limit our practicegery c November 2012
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drugs are never indicated by the FDA approval for pediatric
usage. However a ‘‘band wagon’’ mentality of following
certain parts of the published data yet dispensing with refut-
ing data means we are not providing our patients with the
best service. Human trials should not be conducted by with-
drawal of useful agents from the market place, allowing us
an eventual look back to determine whether the dire predic-
tions came true or whether new complications arose in cer-
tain populations. Our professional societies should continue
to play an active role in defining guidelines without reflex-
ively altering our practice in response to the fear of litiga-
tion. Each of us as physicians needs to critically read the
published data and weigh the pros and cons for our patients
regarding the available therapeutic options. That is the prac-
tice of medicine.References
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